Diabetes drug switch: could a new combo improve blood sugar?

NCT ID NCT06972732

Recruiting now Disease control Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether switching from one diabetes medication (DPP-4 inhibitor) to another (TZD) can better control blood sugar in people with type 2 diabetes who are already taking metformin and an SGLT2 inhibitor. About 204 adults will be randomly assigned to either stay on their current medication or switch to the new combination. The main goal is to see how much HbA1c (a measure of blood sugar control) changes after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin/Pioglitazone (a combination of two drugs: dapagliflozin and pioglitazone)
What this could lead to: If successful, this could show that switching to a TZD (pioglitazone) provides better blood sugar control than staying on a DPP-4 inhibitor for people with type 2 diabetes already taking metformin and an SGLT2 inhibitor.
What could go wrong: This is a relatively small, early-stage (Phase 4) trial with only 204 participants. Results may not apply to everyone with type 2 diabetes, and the new combination may cause side effects like weight gain or fluid retention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

The Catholic University of Korea, Seoul St. Mary's Hospital
RECRUITING

Seoul, Seocho District, 06591, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.